GDC-0927 is primarily investigated for its potential in cancer treatment, particularly in targeting estrogen receptor-positive (ER+) breast cancer. It functions as a selective estrogen receptor degrader (SERD), which means it binds to estrogen receptors and promotes their degradation, thereby inhibiting the growth of hormone-dependent cancer cells. This mechanism is especially beneficial for patients who have developed resistance to traditional hormone therapies like tamoxifen or aromatase inhibitors. Its application is being explored in clinical trials to assess efficacy, safety, and potential use in advanced or metastatic breast cancer cases. Additionally, research is ongoing to determine its utility in combination with other therapies to enhance treatment outcomes.